Intensity Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Intensity Therapeutics (INTS) with a Buy rating and $5 price target Intensity is a clinical stage biotechnology company focused on developing cancer therapy formulations designed for intratumoral administration of chemotherapeutic agents, the analyst tells investors in a research note. The firm says the company is developing a “disruptive treatment” for solid tumors.